https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-earnings-report-preview-what-to-look-for-b524a39e152897b5Pharma Surgeen2026-07-22T11:23:35.000ZWest Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look Forhttps://www.pharmaradar360.com/article/what-leadership-looks-like-the-future-of-esg-in-healthcare-and-biotech-9f6b186470c5f4afPharma Surgeen2026-07-22T11:16:55.000ZWhat Leadership Looks Like: The Future of ESG in Healthcare and Biotechhttps://www.pharmaradar360.com/article/trinity-biotech-plc-announces-plan-to-implement-ads-ratio-change-0b05c44fd3e47cf2Pharma Surgeen2026-07-22T11:15:10.000ZTrinity Biotech Plc Announces Plan to Implement ADS Ratio Changehttps://www.pharmaradar360.com/article/trinity-biotech-plans-mandatory-exchange-of-30-adss-for-1-on-july-24-16e054168fa7ea96Pharma Surgeen2026-07-22T11:15:00.000ZTrinity Biotech Plans Mandatory Exchange of 30 ADSs for 1 on July 24https://www.pharmaradar360.com/article/la-aemps-informa-de-la-retirada-de-equipos-para-cicladora-personal-homechoice-co-84e44065e068ed57Pharma Surgeen2026-07-22T11:07:30.000ZLa AEMPS informa de la retirada de equipos para Cicladora Personal HomeChoice con cassette y 4 líneashttps://www.pharmaradar360.com/article/in-vitro-74ac217207dda3c4Pharma Surgeen2026-07-22T11:03:57.000ZΣχετικά με την προσφορά οικονομικών παροχών σε συμμετέχοντες σε κλινικές δοκιμές με φάρμακα, κλινικές έρευνες με ιατροτεχνολογικά προϊόντα και μελέτες επιδόσεων με in vitro διαγνωστικά προϊόνταhttps://www.pharmaradar360.com/article/tilorone-dihydrochloride-market-growth-forecast-to-2035-pharmaceutical-r-d-and-i-3b7b927954af9822Pharma Surgeen2026-07-22T11:01:13.000ZTilorone Dihydrochloride Market Growth Forecast to 2035: Pharmaceutical R&D and Industrial Applications Drive Expansion - News and Statisticshttps://www.pharmaradar360.com/article/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-diff-eb098c2f1b06a9a0Pharma Surgeen2026-07-22T11:00:06.000ZAnnual epidemiological commentary: Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2025 to 2026https://www.pharmaradar360.com/article/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman-77d1117229596041Pharma Surgeen2026-07-22T11:00:00.000ZTiziana Life Sciences Announces Purchase of Shares by Executive Chairmanhttps://www.pharmaradar360.com/article/ftse4good-index-series-3-f60590ce87bfbfa9Pharma Surgeen2026-07-22T11:00:00.000ZFTSE4Good Index Seriesの構成銘柄に3年連続で選定https://www.pharmaradar360.com/article/okyo-pharma-plans-phase-3-trial-for-single-dose-eye-pain-drug-e91f89f515d51611Pharma Surgeen2026-07-22T11:00:00.000ZOKYO Pharma Plans Phase 3 Trial for Single-Dose Eye Pain Drughttps://www.pharmaradar360.com/article/the-biotech-recovery-gathers-speed-in-q2-b4890d4f77cbc05cPharma Surgeen2026-07-22T10:45:00.000ZThe biotech recovery gathers speed in Q2https://www.pharmaradar360.com/article/acetonitrile-market-to-reach-usd-567-5-million-by-2035-as-pharmaceutical-manufac-ed0557192a970391Pharma Surgeen2026-07-22T10:38:00.000ZAcetonitrile Market to Reach USD 567.5 Million by 2035 as Pharmaceutical Manufacturing and Lithium-Ion Battery Demand Accelerate Global Growthhttps://www.pharmaradar360.com/article/biotech-industry-backs-fda-hiring-push-seeks-science-led-drug-reviews-3022b0aa8386c92fPharma Surgeen2026-07-22T10:34:26.000ZBiotech industry backs FDA hiring push, seeks science-led drug reviewshttps://www.pharmaradar360.com/article/former-pharmaceutical-leader-hank-mckinnell-lends-expertise-to-teton-county-sher-889b09ba0d78fcddPharma Surgeen2026-07-22T10:30:00.000ZFormer pharmaceutical leader Hank McKinnell lends expertise to Teton County Sheriff's Officehttps://www.pharmaradar360.com/article/2026-2853b437266b5866Pharma Surgeen2026-07-22T10:24:26.000ZΕκτέλεση προϋπολογισμού ΕΟΦ μηνός Ιουνίου 2026https://www.pharmaradar360.com/article/api-innovation-center-develops-national-fragility-index-to-diversify-pharmaceuti-7d1a53f0a97f0a57Pharma Surgeen2026-07-22T10:18:44.000ZAPI Innovation Center Develops National Fragility Index to Diversify Pharmaceutical Supply Chainshttps://www.pharmaradar360.com/article/2500143f-bentalya-vial-5-25-mg-10ml-9455c0b9112f719cPharma Surgeen2026-07-22T10:18:26.000ZΑνάκληση της παρτίδας 2500143F, του φαρμακευτικού προϊόντος BENTALYA VIAL 5×25 MG/10MLhttps://www.pharmaradar360.com/article/mdd-class-iib-overstritch-suture-cinch-and-sature-cinch-long-90b83cbaff3689fbPharma Surgeen2026-07-22T10:14:31.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIb, OverStritch Suture Cinch and Sature Cinch-Long, (Εξάρτημα ασφάλισης ράμματος και εξάρτημα ασφάλισης ράμματος μεγάλου μήκους)https://www.pharmaradar360.com/article/biotech-experts-want-fda-drug-reviews-based-on-science-not-politics-1b5b962723a2efd2Pharma Surgeen2026-07-22T10:07:45.000ZBiotech experts want FDA drug reviews based on science, not politicshttps://www.pharmaradar360.com/article/hepatitis-b-bepirovirsen-helps-1-in-5-achieve-functional-cure-34cdc10a7a893f26Pharma Surgeen2026-07-22T10:07:27.000ZHepatitis B: Bepirovirsen helps 1 in 5 achieve functional curehttps://www.pharmaradar360.com/article/biotech-experts-want-fda-drug-reviews-based-on-science-not-politics-1af86d5109d9d687Pharma Surgeen2026-07-22T10:00:00.000ZBiotech experts want FDA drug reviews based on science, not politicshttps://www.pharmaradar360.com/article/la-aemps-y-plena-inclusion-madrid-lanzan-una-guia-en-lectura-facil-para-promover-aa8555377b3bfa94Pharma Surgeen2026-07-22T09:54:33.000ZLa AEMPS y Plena Inclusión Madrid lanzan una guía en lectura fácil para promover una exposición solar segurahttps://www.pharmaradar360.com/article/rhode-island-fugitive-convicted-of-rape-captured-after-decades-as-l-a-biotech-ex-c8807e5dad8e7d55Pharma Surgeen2026-07-22T09:43:39.000ZRhode Island fugitive convicted of rape captured after decades as L.A. biotech executivehttps://www.pharmaradar360.com/article/samsung-bioepis-partners-with-prazer-therapeutics-bionsight-on-open-innovation-5a7878aab0b161a7Pharma Surgeen2026-07-22T09:25:19.000ZSamsung Bioepis partners with Prazer Therapeutics, Bionsight on open innovationhttps://www.pharmaradar360.com/article/growth-and-skills-levy-a-catalyst-for-the-uk-pharmaceutical-industry-f480d098599079a2Pharma Surgeen2026-07-22T09:21:11.000ZGrowth and skills levy: A catalyst for the UK pharmaceutical industry?https://www.pharmaradar360.com/article/corporate-report-mhra-policy-for-handling-corporate-conflicts-of-interest-f11ef4de23117133Pharma Surgeen2026-07-22T09:15:59.000ZCorporate report: MHRA: policy for handling corporate conflicts of interesthttps://www.pharmaradar360.com/article/biotech-s-takeover-boom-may-be-running-out-of-buyers-73838381dcf805e0Pharma Surgeen2026-07-22T09:14:00.000ZBiotech's takeover boom may be running out of buyershttps://www.pharmaradar360.com/article/automatic-tablet-counting-system-market-forecast-points-higher-toward-2035-drive-5299a61c8fbb8e7aPharma Surgeen2026-07-22T09:11:13.000ZAutomatic Tablet Counting System Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Serialization Mandateshttps://www.pharmaradar360.com/article/pharmaceutical-technology-e9121f77fe2ee605Pharma Surgeen2026-07-22T09:10:22.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/hsbc-holdings-plc-has-28-79-million-holdings-in-teva-pharmaceutical-industries-l-cb66a9170c57d3c0Pharma Surgeen2026-07-22T09:01:52.000ZHsbc Holdings PLC Has $28.79 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/peptides-get-their-regulatory-closeup-8cf1ae39af56d3c6Pharma Surgeen2026-07-22T09:00:00.000ZPeptides get their regulatory closeuphttps://www.pharmaradar360.com/article/la-ce-publica-unas-recomendaciones-para-identificar-cuando-esta-justificada-la-p-eddd2e7b5aa24ca9Pharma Surgeen2026-07-22T08:47:25.000ZLa CE publica unas recomendaciones para identificar cuándo está justificada la prescripción en cascada de medicamentos veterinarioshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-projected-to-post-earnings-on-wednesday-50f24f00b3914edbPharma Surgeen2026-07-22T08:46:27.000ZTeva Pharmaceutical Industries (TEVA) Projected to Post Earnings on Wednesdayhttps://www.pharmaradar360.com/article/0349209e7d5f9e4cPharma Surgeen2026-07-22T08:43:43.000ZΕπίσημη επίσκεψη της Διοίκησης του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ) στην Κυπριακή Δημοκρατία για την ενίσχυση της συνεργασίας στον τομέα του ρυθμιστικού πλαισίου των φαρμάκωνhttps://www.pharmaradar360.com/article/77-800-shares-in-teva-pharmaceutical-industries-ltd-teva-acquired-by-barometer-c-7a89ad11278c2ae3Pharma Surgeen2026-07-22T08:42:26.000Z77,800 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Barometer Capital Management Inc.https://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-mayo-de-2026-83443e2df3d0b479Pharma Surgeen2026-07-22T08:01:09.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Mayo de 2026https://www.pharmaradar360.com/article/biotech-company-files-bankruptcy-petition-against-smolt-producer-d08327e6ddca2fc3Pharma Surgeen2026-07-22T07:57:45.000ZBiotech company files bankruptcy petition against smolt producerhttps://www.pharmaradar360.com/article/biotech-hair-growth-brand-re-you-launches-2edb8f54a86fffd8Pharma Surgeen2026-07-22T07:25:20.000ZBiotech Hair Growth Brand Re:You Launcheshttps://www.pharmaradar360.com/article/first-aid-a-short-week-biotech-rolls-on-c21eb91bf09a2d68Pharma Surgeen2026-07-22T07:18:36.000ZFIRST AID: A short week, biotech rolls onhttps://www.pharmaradar360.com/article/wegovy-seeks-korea-approval-to-treat-mash-expanding-beyond-obesity-chosunbiz-0347c5067b62ff6dPharma Surgeen2026-07-22T07:13:00.000ZWegovy seeks Korea approval to treat MASH, expanding beyond obesity - CHOSUNBIZhttps://www.pharmaradar360.com/article/singapore-based-biotech-startup-tikva-allocell-closes-8-m-series-a-funding-round-70dc9bec44812481Pharma Surgeen2026-07-22T07:12:27.000ZSingapore-based biotech startup Tikva Allocell closes $8 M Series A funding roundhttps://www.pharmaradar360.com/article/solvent-dehydration-chemicals-market-to-reach-usd-2-078-2-million-by-2036-as-pha-697c8ef62e53f5c8Pharma Surgeen2026-07-22T07:04:06.000ZSolvent Dehydration Chemicals Market to Reach USD 2,078.2 Million by 2036 as Pharmaceutical Manufacturing and High-Purity Solvent Recovery Accelerate Global Demandhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hanmi-pharmaceutical-co-ltd-krx-128940-22853b0802c8b997Pharma Surgeen2026-07-22T06:54:52.000ZEnterprise value to EBITDA forward of Hanmi Pharmaceutical Co., Ltd. – KRX:128940https://www.pharmaradar360.com/article/armata-submits-phase-3-protocol-for-ap-sa02-bacteriophage-in-s-aureus-bacteremia-e0013c0168187e8dPharma Surgeen2026-07-22T06:54:11.000ZArmata Submits Phase 3 Protocol for AP-SA02 Bacteriophage in S. aureus Bacteremiahttps://www.pharmaradar360.com/article/major-new-pharmaceutical-policy-us-tariffs-on-generic-drugs-to-double-progressiv-a87ccc409cf9b602Pharma Surgeen2026-07-22T06:24:19.000ZMajor new pharmaceutical policy! US tariffs on generic drugs to double progressively, up to 200%https://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-l-a-biotech-exec-4f2e50e4d0c9f39fPharma Surgeen2026-07-22T06:11:33.000ZFugitive doctor on run for 21 years was living as L.A. biotech exechttps://www.pharmaradar360.com/article/why-is-sun-pharmaceutical-industries-stock-falling-today-dc875cc497ed52a8Pharma Surgeen2026-07-22T06:11:15.000ZWhy is Sun Pharmaceutical Industries stock falling today?https://www.pharmaradar360.com/article/fda-warns-of-recalled-allergy-drug-over-contamination-risk-89737f8b1a3e0b43Pharma Surgeen2026-07-22T05:48:41.000ZFDA Warns of Recalled Allergy Drug Over Contamination Riskhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-beijing-aosaikang-pharmaceutical-co-ltd-class-a-szs-f01068bb4cb409d0Pharma Surgeen2026-07-22T05:45:10.000ZPrice to earnings forward of Beijing Aosaikang Pharmaceutical Co., Ltd. Class A – SZSE:002755https://www.pharmaradar360.com/article/u-s-biotech-ceo-explains-why-he-chose-hong-kong-for-primary-listing-39f8c09a675d49daPharma Surgeen2026-07-22T05:13:00.000ZU.S. biotech CEO explains why he chose Hong Kong for primary listinghttps://www.pharmaradar360.com/article/ing-podcast-examines-china-s-biotech-rise-and-shifting-global-pharma-order-9e8aa15348b19d64Pharma Surgeen2026-07-22T05:11:50.000ZING podcast examines China’s biotech rise and shifting global pharma orderhttps://www.pharmaradar360.com/article/thailand-courts-korean-investment-in-biotech-wellness-sectors-2f4b41ea1b95789bPharma Surgeen2026-07-22T04:52:32.000ZThailand courts Korean investment in biotech, wellness sectorshttps://www.pharmaradar360.com/article/lonza-raises-core-profit-margin-target-after-solid-first-half-10849dd4d5c6f246Pharma Surgeen2026-07-22T04:51:00.000ZLonza raises core profit margin target after solid first halfhttps://www.pharmaradar360.com/article/where-to-find-healthy-profits-in-biotech-bcb3792bc295d6d1Pharma Surgeen2026-07-22T04:00:00.000ZWhere to find healthy profits in biotechhttps://www.pharmaradar360.com/article/sex-offender-a-fugitive-for-21-years-hid-in-plain-sight-as-a-yacht-owning-l-a-bi-a16e2b45e4e87735Pharma Surgeen2026-07-22T03:43:00.000ZSex offender, a fugitive for 21 years, hid in plain sight as a yacht-owning L.A. biopharma exechttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-overvalued-on-its-kb801-patent-data-update-ff981b788ad4fc4fPharma Surgeen2026-07-22T03:37:51.000ZIs Krystal Biotech (KRYS) Overvalued On Its KB801 Patent Data Update?https://www.pharmaradar360.com/article/the-ai-ebb-gives-way-to-biotech-as-winners-emerge-in-the-u-s-ipo-market-4fba6c2638aa343dPharma Surgeen2026-07-22T02:55:14.000ZThe AI Ebb Gives Way to Biotech as Winners Emerge in the U.S. IPO Markethttps://www.pharmaradar360.com/article/bio-asia-taiwan-2026-unites-60-countries-showcasing-taiwan-as-a-global-biotech-i-aef5b4d99c9246c0Pharma Surgeen2026-07-22T02:09:00.000ZBIO Asia-Taiwan 2026 Unites 60 Countries, Showcasing Taiwan as a Global Biotech Innovation Partnerhttps://www.pharmaradar360.com/article/trump-threatens-to-impose-tariffs-on-generic-drugs-666584971fb2e9e0Pharma Surgeen2026-07-22T01:24:53.000ZTrump Threatens to Impose Tariffs on Generic Drugshttps://www.pharmaradar360.com/article/msd-advances-korea-linked-eye-drug-starts-four-phase-3-trials-vs-eylea-chosunbiz-e916c5eae1d70710Pharma Surgeen2026-07-22T01:18:00.000ZMSD advances Korea-linked eye drug, starts four phase 3 trials vs Eylea - CHOSUNBIZhttps://www.pharmaradar360.com/article/trump-plans-generic-drug-tariffs-from-2028-with-two-year-delay-testing-u-s-onsho-d5e8b12ef9caf861Pharma Surgeen2026-07-22T01:17:00.000ZTrump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring pushhttps://www.pharmaradar360.com/article/is-your-allergy-medicine-safe-fda-recalls-antihistamine-tablets-over-life-threat-103a9c835338e8bePharma Surgeen2026-07-22T00:57:11.000ZIs Your Allergy Medicine Safe? FDA Recalls Antihistamine Tablets Over Life-Threatening Contamination Concernshttps://www.pharmaradar360.com/article/shapiro-administration-launches-125m-fund-for-biotech-startups-3852c653f994f3f6Pharma Surgeen2026-07-22T00:55:49.000ZShapiro administration launches $125M fund for biotech startupshttps://www.pharmaradar360.com/article/trump-says-he-will-impose-tariffs-on-generic-drugs-starting-in-august-2028-d65d92ace69a623fPharma Surgeen2026-07-22T00:52:00.000ZTrump says he will impose tariffs on generic drugs starting in August 2028https://www.pharmaradar360.com/article/kolon-tissuegene-plunges-again-as-us-phase-3-for-arthritis-therapy-fails-chosunb-4218c157885dbd2dPharma Surgeen2026-07-22T00:50:00.000ZKolon TissueGene plunges again as US phase 3 for arthritis therapy fails - CHOSUNBIZhttps://www.pharmaradar360.com/article/aribio-to-present-ar1001-phase-3-results-at-ctad-2026-in-boston-ef828346a933baaePharma Surgeen2026-07-22T00:31:25.000ZAriBio to present AR1001 phase 3 results at CTAD 2026 in Bostonhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-ff80dad4529023a8Pharma Surgeen2026-07-22T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-2b121d00efb8d795Pharma Surgeen2026-07-22T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-601ca10e2cc85c2bPharma Surgeen2026-07-22T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-e1e7b14095cbfee3Pharma Surgeen2026-07-22T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5331b1594f6ef544Pharma Surgeen2026-07-22T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-409698ebf7a054bcPharma Surgeen2026-07-22T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-d25286b7ae5dea4aPharma Surgeen2026-07-22T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-90b1813202160774Pharma Surgeen2026-07-22T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c36d9feae1adef2aPharma Surgeen2026-07-22T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-41d29e58c5900668Pharma Surgeen2026-07-22T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-8e5ce6af3b749747Pharma Surgeen2026-07-22T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-81c3eb42cd4011a2Pharma Surgeen2026-07-22T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-421cdfd06160e1e8Pharma Surgeen2026-07-22T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-5ed03e84f5e7c483Pharma Surgeen2026-07-22T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/view-latest-results-ec5f7049f7dae5acPharma Surgeen2026-07-22T00:00:00.000ZView latest resultshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-generic-for-administration-e37562db68cd460dPharma Surgeen2026-07-22T00:00:00.000ZSubmission for Office of Management and Budget Review; Generic for Administration for Children and Families Program Monitoring Activitieshttps://www.pharmaradar360.com/article/determination-that-rasuvo-methotrexate-solution-27-5-milligrams-0-55-milliliter-5ac808971db7c933Pharma Surgeen2026-07-22T00:00:00.000ZDetermination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-fd81174b1386a311Pharma Surgeen2026-07-22T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-ce3e4f8d6652e063Pharma Surgeen2026-07-22T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notifications Submissionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-a140cd12eef246faPharma Surgeen2026-07-22T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Advanced Nursing Education Program Specific Form OMB No. 0906-0089-Revisionhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cerilliant-corporation-c3ddeba7d306409fPharma Surgeen2026-07-22T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cerilliant Corporationhttps://www.pharmaradar360.com/article/nsg-bio-accelerates-breakthrough-biotech-innovation-in-singapore-75992e25bf7ad0a5Pharma Surgeen2026-07-22T00:00:00.000ZNSG Bio Accelerates Breakthrough Biotech Innovation in Singaporehttps://www.pharmaradar360.com/article/united-therapeutics-corporation-to-report-second-quarter-2026-financial-results-9045d645d5be4c52Pharma Surgeen2026-07-22T00:00:00.000ZUnited Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026https://www.pharmaradar360.com/article/statistical-integration-of-gwas-eqtl-and-pqtl-data-for-multi-omics-analysis-of-a-0968cbd76144850aPharma Surgeen2026-07-22T00:00:00.000ZStatistical integration of GWAS, eQTL and pQTL data for multi-omics analysis of Alzheimer's Diseasehttps://www.pharmaradar360.com/article/kras-g12c-targeted-therapy-strategy-for-lung-cancer-mechanism-clinical-practice-96344c0257245e39Pharma Surgeen2026-07-22T00:00:00.000ZKRAS G12C-Targeted Therapy Strategy for Lung Cancer: Mechanism, Clinical Practice and Challengeshttps://www.pharmaradar360.com/article/clinical-outcomes-of-arthroscopic-stabilization-procedures-in-patients-with-shou-89aa9f858bbf2d83Pharma Surgeen2026-07-22T00:00:00.000ZClinical outcomes of arthroscopic stabilization procedures in patients with shoulder dislocation combined with posttraumatic adhesive capsulitishttps://www.pharmaradar360.com/article/clinical-and-diagnostic-significance-of-vascular-and-metabolic-factors-in-the-de-d04db77dc59fc72dPharma Surgeen2026-07-22T00:00:00.000ZClinical and Diagnostic Significance of Vascular and Metabolic Factors in the Development of Cognitive Impairment in Patients with Chronic Somatic Diseaseshttps://www.pharmaradar360.com/article/prolactinoma-associated-with-l-dopa-resistant-hyperprolactinemia-in-a-child-with-bc4d4db35afc9b00Pharma Surgeen2026-07-22T00:00:00.000ZProlactinoma Associated with L-Dopa–Resistant Hyperprolactinemia in a Child with Tetrahydropterin (BH4) Deficiencyhttps://www.pharmaradar360.com/article/real-world-risk-assessment-of-drug-induced-cytokine-release-syndrome-analysis-of-14ca5e9fe63fa860Pharma Surgeen2026-07-22T00:00:00.000ZReal-world risk assessment of drug-induced cytokine release syndrome: Analysis of the Food and Drug Administration Adverse Event Reporting Systemhttps://www.pharmaradar360.com/article/from-susceptibility-to-disease-severity-re-discovering-the-clinical-role-of-mmp-b98770429d3d0395Pharma Surgeen2026-07-22T00:00:00.000ZFrom Susceptibility to Disease Severity: Re-Discovering the Clinical Role of MMP-12 Genotypes in Asthmahttps://www.pharmaradar360.com/article/hypofractionated-versus-conventional-postmastectomy-radiotherapy-in-implant-base-1caa43ef2310d0b7Pharma Surgeen2026-07-22T00:00:00.000ZHypofractionated Versus Conventional Postmastectomy Radiotherapy in Implant-Based Breast Reconstruction: A Systematic Review and Meta-Analysishttps://www.pharmaradar360.com/article/association-between-metabolic-obesity-phenotypes-and-alcohol-associated-fatty-li-c3a28c2679ffecc8Pharma Surgeen2026-07-22T00:00:00.000ZAssociation Between Metabolic Obesity Phenotypes and Alcohol-Associated Fatty Liver Disease Among US Adults: A NHANES 2013–2018 Analysishttps://www.pharmaradar360.com/article/the-cally-index-in-critical-illness-risk-stratification-and-its-potential-role-i-2435e6a0331bd635Pharma Surgeen2026-07-22T00:00:00.000ZThe CALLY Index in Critical Illness: Risk Stratification and Its Potential Role in Clinical Monitoringhttps://www.pharmaradar360.com/article/apert-syndrome-oral-maxillofacial-and-dental-management-a-narrative-clinical-rev-bdf4d39ca3f676aePharma Surgeen2026-07-22T00:00:00.000ZApert Syndrome: Oral, Maxillofacial and Dental Management—A Narrative Clinical Reviewhttps://www.pharmaradar360.com/article/retracted-kshirsagar-et-al-a-combination-therapy-of-urolithin-a-egcg-has-stronge-bd3d023a8ad0ee8bPharma Surgeen2026-07-22T00:00:00.000ZRETRACTED: Kshirsagar et al. A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease. Cells 2022, 11, 2660https://www.pharmaradar360.com/article/cancer-associated-fibroblast-heterogeneity-and-extracellular-matrix-remodeling-a-51770aa11e094735Pharma Surgeen2026-07-22T00:00:00.000ZCancer-Associated Fibroblast Heterogeneity and Extracellular Matrix Remodeling as Orchestrators of Drug Resistance in Upper Gastrointestinal Cancers: Insights from Spatial Multi-Omics and Therapeutic Implicationshttps://www.pharmaradar360.com/article/clinical-equipoise-and-ethical-challenges-in-expanding-endovascular-stroke-throm-b95e06e9a95f696bPharma Surgeen2026-07-22T00:00:00.000ZClinical equipoise and ethical challenges in expanding endovascular stroke thrombectomy practicehttps://www.pharmaradar360.com/article/intrapelvic-migration-of-a-trial-femoral-head-during-direct-anterior-approach-to-8c298d8f4d08d1a5Pharma Surgeen2026-07-22T00:00:00.000ZIntrapelvic migration of a trial femoral head during direct anterior approach total hip arthroplasty: a case report and literature reviewhttps://www.pharmaradar360.com/article/analysis-of-factors-influencing-post-pandemic-sleep-quality-among-hospital-clini-6e43f9654e80a8ddPharma Surgeen2026-07-22T00:00:00.000ZAnalysis of factors influencing post-pandemic sleep quality among hospital clinical staff in Haikou, Chinahttps://www.pharmaradar360.com/article/implications-of-isonicotinylation-associated-patterns-in-nk-cells-in-the-pathoge-49677c34a724bf00Pharma Surgeen2026-07-22T00:00:00.000ZImplications of isonicotinylation-associated patterns in NK cells in the pathogenesis of Kawasaki disease: evidence from artificial intelligence-driven multi-omics and clinical validationhttps://www.pharmaradar360.com/article/a-6-week-ketogenic-diet-in-treatment-resistant-depression-a-prospective-single-a-9d813c0230bd0690Pharma Surgeen2026-07-22T00:00:00.000ZA 6-week ketogenic diet in treatment-resistant depression: a prospective single-arm feasibility pilot trialhttps://www.pharmaradar360.com/article/safety-of-transcutaneous-electrical-stimulation-potentiating-recovery-in-acute-s-f679227ca0250fafPharma Surgeen2026-07-22T00:00:00.000ZSafety of transcutaneous electrical stimulation potentiating recovery in acute spinal cord injury syndromes: a trial protocolhttps://www.pharmaradar360.com/article/efficacy-of-acupuncture-for-patients-with-parkinson-s-disease-related-constipati-fd6e4404d30672efPharma Surgeen2026-07-22T00:00:00.000ZEfficacy of acupuncture for patients with Parkinson’s disease–related constipation: study protocol for a randomized controlled, double-blind trialhttps://www.pharmaradar360.com/article/the-role-of-otud1-mediated-deubiquitination-in-disease-pathogenesis-from-molecul-e8b57327a04b589aPharma Surgeen2026-07-22T00:00:00.000ZThe role of OTUD1-mediated deubiquitination in disease pathogenesis: from molecular mechanisms to clinical translationhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-mesenchymal-stem-cell-transplantation-for-progressive-mul-5a24a2a89e09a613Pharma Surgeen2026-07-22T00:00:00.000ZEfficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials with clinical implications for patient stratification and treatment optimizationhttps://www.pharmaradar360.com/article/a-mini-review-of-genome-predicted-lactam-susceptibility-in-streptococcus-pneumon-7bb891af7d4db5fePharma Surgeen2026-07-22T00:00:00.000ZA mini review of genome-predicted β-lactam susceptibility in Streptococcus pneumoniae: from PBP profiles to potential clinical interpretationhttps://www.pharmaradar360.com/article/ferroptosis-in-liver-diseases-molecular-mechanisms-biomarker-potential-and-clini-74c8050c30588e26Pharma Surgeen2026-07-22T00:00:00.000ZFerroptosis in liver diseases: molecular mechanisms, biomarker potential, and clinical translationhttps://www.pharmaradar360.com/article/on-the-distance-eccentricity-indices-of-thorn-graphs-qspr-and-dft-applications-t-19033bfbefcabd57Pharma Surgeen2026-07-22T00:00:00.000ZOn the distance eccentricity indices of thorn graphs: QSPR and DFT applications to ocular drug design and molecular property predictionhttps://www.pharmaradar360.com/article/special-pre-trial-investigation-in-absentia-in-the-criminal-process-of-ukraine-e-8d84bb84f4277412Pharma Surgeen2026-07-22T00:00:00.000ZSpecial pre-trial investigation (in absentia) in the criminal process of Ukraine: evidentiary nature of grounds, subject of proof and judicial controlhttps://www.pharmaradar360.com/article/snapc4-related-neurodevelopmental-disorder-defines-a-stage-dependent-spliceosomo-f441b5df345e80d6Pharma Surgeen2026-07-22T00:00:00.000ZSNAPC4-related neurodevelopmental disorder defines a stage-dependent spliceosomopathy with heterogeneous clinical trajectorieshttps://www.pharmaradar360.com/article/pathological-fractures-in-rare-bone-diseases-clinical-cases-5a2a7d40798e097ePharma Surgeen2026-07-22T00:00:00.000ZPathological Fractures in Rare Bone Diseases: Clinical Caseshttps://www.pharmaradar360.com/article/smart-magnetic-carrier-for-controlled-anticancer-drug-delivery-synthesis-charact-6fbbc4293bd2a339Pharma Surgeen2026-07-22T00:00:00.000ZSmart magnetic carrier for controlled anticancer drug delivery: synthesis, characterization, and doxorubicin releasehttps://www.pharmaradar360.com/article/from-hospital-care-to-home-bringing-laboratory-led-poct-to-home-care-for-sodium-a49549bef837d294Pharma Surgeen2026-07-22T00:00:00.000ZFrom hospital care to home: bringing laboratory-led POCT to home care for sodium monitoring in pediatric patients with craniopharyngiomahttps://www.pharmaradar360.com/article/temporal-synchrony-promotes-motor-recovery-and-ipsilesional-cortical-reorganizat-d6e2d1364ed9aaf2Pharma Surgeen2026-07-22T00:00:00.000ZTemporal synchrony promotes motor recovery and ipsilesional cortical reorganization in BCI-based stroke rehabilitation: a randomized controlled trialhttps://www.pharmaradar360.com/article/do-video-animations-and-3-d-skull-models-reduce-preoperative-anxiety-in-bimaxill-984b8be63703f2f6Pharma Surgeen2026-07-22T00:00:00.000ZDo video animations and 3-D skull models reduce preoperative anxiety in bimaxillary orthognathic surgery patients? Randomized controlled trialhttps://www.pharmaradar360.com/article/patient-and-implant-level-factors-associated-with-peri-implant-diseases-a-retros-eb63ca43dc440ae4Pharma Surgeen2026-07-22T00:00:00.000ZPatient- and implant-level factors associated with peri-implant diseases: a retrospective clinical and radiographic study of 968 implantshttps://www.pharmaradar360.com/article/tenecteplase-efficacy-in-patients-with-distal-occlusions-secondary-analysis-of-t-0febfd24986800e0Pharma Surgeen2026-07-22T00:00:00.000ZTenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trialhttps://www.pharmaradar360.com/article/fecal-microbiota-transplantation-based-treatment-protocol-for-chronic-insomnia-d-89a96eb6ad9cc0d7Pharma Surgeen2026-07-22T00:00:00.000ZFecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trialhttps://www.pharmaradar360.com/article/art-therapy-marketing-and-fundraising-cost-and-revenue-patterns-in-u-s-hospital-c22870bcfcfb1956Pharma Surgeen2026-07-22T00:00:00.000ZArt therapy, marketing and fundraising: cost and revenue patterns in U.S. hospital foundationshttps://www.pharmaradar360.com/article/harnessing-the-potential-of-spider-silk-proteins-as-emerging-biomaterials-for-dr-d21c2018444bb8b8Pharma Surgeen2026-07-22T00:00:00.000ZHarnessing the potential of spider silk proteins as emerging biomaterials for drug delivery: classification, comparative evaluation and future perspectives.https://www.pharmaradar360.com/article/e-resources-relevant-to-machine-learning-tools-for-medicinal-chemistry-fc47554fb08f2851Pharma Surgeen2026-07-22T00:00:00.000Ze-Resources Relevant to Machine Learning Tools for Medicinal Chemistryhttps://www.pharmaradar360.com/article/chemical-language-model-applications-in-medicinal-chemistry-bfe5577dd8e764caPharma Surgeen2026-07-22T00:00:00.000ZChemical Language Model Applications in Medicinal Chemistryhttps://www.pharmaradar360.com/article/machine-learning-in-drug-induced-adverse-reaction-modeling-case-studies-of-drug-e8d0ac0acec0f1c8Pharma Surgeen2026-07-22T00:00:00.000ZMachine Learning in Drug-induced Adverse Reaction Modeling: Case Studies of Drug-induced Cardiotoxicity Modelinghttps://www.pharmaradar360.com/article/machine-learning-in-drug-drug-interactions-28dfb21a4e30b3b2Pharma Surgeen2026-07-22T00:00:00.000ZMachine Learning in Drug–Drug Interactionshttps://www.pharmaradar360.com/article/machine-learning-in-predicting-the-physicochemical-properties-of-drug-candidates-484689d7e517f2eePharma Surgeen2026-07-22T00:00:00.000ZMachine Learning in Predicting the Physicochemical Properties of Drug Candidateshttps://www.pharmaradar360.com/article/exploratory-analyses-of-potential-moderators-of-a-personalized-intervention-to-r-d2cba4c390ee6d15Pharma Surgeen2026-07-22T00:00:00.000ZExploratory analyses of potential moderators of a personalized intervention to reduce preoperative anxiety: a secondary analysis of a randomized clinical trialhttps://www.pharmaradar360.com/article/mid-term-clinical-and-radiologic-outcomes-of-augmented-microfracture-with-decell-afe89e92219ea91ePharma Surgeen2026-07-22T00:00:00.000ZMid-term clinical and radiologic outcomes of augmented microfracture with decellularized particulated costal allocartilage for knee cartilage defects: four-year prospective case serieshttps://www.pharmaradar360.com/article/optimizing-the-study-planning-phase-in-an-investigator-initiated-multicenter-cli-75cb79a73e7debcePharma Surgeen2026-07-22T00:00:00.000ZOptimizing the Study Planning Phase in an Investigator-Initiated Multicenter Clinical Trial: Mapping the Process into a Blueprinthttps://www.pharmaradar360.com/article/evaluation-of-the-anticancer-and-antibacterial-activities-of-several-new-drug-co-0ae17540ee54f69dPharma Surgeen2026-07-22T00:00:00.000ZEvaluation of the anticancer and antibacterial activities of several new drug conjugated systems based on mefenamic acidhttps://www.pharmaradar360.com/article/enterovirus-encephalitis-developing-after-treatment-for-follicular-lymphoma-a-ca-bb358164822b08afPharma Surgeen2026-07-22T00:00:00.000ZEnterovirus Encephalitis Developing After Treatment for Follicular Lymphoma: A Case Reporthttps://www.pharmaradar360.com/article/unlocking-the-epigenetic-potential-of-ascorbic-acid-vitamin-c-in-cancer-therapy-51dc63cd19f0aac4Pharma Surgeen2026-07-22T00:00:00.000ZUnlocking the epigenetic potential of ascorbic acid (Vitamin C) in cancer therapyhttps://www.pharmaradar360.com/article/pneumocystis-jirovecii-pneumonia-and-prophylaxis-in-patients-with-solid-tumours-227376e2a8429381Pharma Surgeen2026-07-22T00:00:00.000ZPneumocystis jirovecii pneumonia and prophylaxis in patients with solid tumours: a narrative reviewhttps://www.pharmaradar360.com/article/nano-drug-delivery-of-a-new-scfv-based-immunotoxin-by-chitosan-nanoparticles-upg-e9dd515dfe06ca64Pharma Surgeen2026-07-22T00:00:00.000ZNano drug delivery of a new scfv-based immunotoxin by chitosan nanoparticles upgrades its efficiency against breast cancerhttps://www.pharmaradar360.com/article/early-termination-of-a-first-in-human-trial-of-a-swallowable-self-expanding-intr-9f8677b4aef5c64dPharma Surgeen2026-07-22T00:00:00.000ZEarly Termination of a First-in-Human Trial of a Swallowable Self-Expanding Intragastric Balloon (IGBalloon©) Due to Small Bowel Obstructionhttps://www.pharmaradar360.com/article/impact-of-updated-nccn-guidelines-on-clinical-management-and-risk-communication-b1ec4c39f2cf973ePharma Surgeen2026-07-22T00:00:00.000ZImpact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancerhttps://www.pharmaradar360.com/article/clinical-professional-formation-among-social-work-students-professional-identity-a673dda22a6c13a7Pharma Surgeen2026-07-22T00:00:00.000ZClinical Professional Formation Among Social Work Students: Professional Identity, Clinical Self-Efficacy, Career Intention, and Commitmenthttps://www.pharmaradar360.com/article/systematic-review-of-extracellular-vesicle-based-liquid-biopsy-for-leptomeningea-074cc62d9d186d85Pharma Surgeen2026-07-22T00:00:00.000ZSystematic review of extracellular vesicle-based liquid biopsy for leptomeningeal metastasis: current evidence and future directionshttps://www.pharmaradar360.com/article/from-fatal-events-to-chronic-disability-the-evolving-clinical-landscape-of-pm2-5-9284ad1e1c5c8d1fPharma Surgeen2026-07-22T00:00:00.000ZFrom fatal events to chronic disability: The evolving clinical landscape of PM2.5-attributable hemorrhagic stroke in China (1990–2050)https://www.pharmaradar360.com/article/predicting-the-risk-of-bone-erosion-in-rheumatoid-arthritis-using-a-shap-based-i-9dae500c8f082fb2Pharma Surgeen2026-07-22T00:00:00.000ZPredicting the risk of bone erosion in rheumatoid arthritis using a SHAP-based interpretable machine learning modelhttps://www.pharmaradar360.com/article/comparative-outcomes-of-aflibercept-8-mg-and-faricimab-in-neovascular-amd-refrac-1c946ecff7ec3c7aPharma Surgeen2026-07-22T00:00:00.000ZComparative outcomes of aflibercept 8 mg and faricimab in neovascular AMD refractory to aflibercept 2 mghttps://www.pharmaradar360.com/article/clinical-pharmacological-medication-reviews-for-insurants-of-a-german-statutory-21b8b9efaa65cc1bPharma Surgeen2026-07-22T00:00:00.000ZClinical-pharmacological medication reviews for insurants of a German statutory health insurance fund (Kaufmännische Krankenkasse (KKH)): a 5-year retrospective analysis (2019–2023)https://www.pharmaradar360.com/article/diphy-an-exploratory-tool-for-diurnal-physiology-and-tests-timing-in-clinical-pr-b92e09e5fbb4f7d8Pharma Surgeen2026-07-22T00:00:00.000ZDiPHY: An Exploratory Tool for Diurnal Physiology and Tests Timing in Clinical Practicehttps://www.pharmaradar360.com/article/enliven-therapeutics-soaring-stock-faces-a-570-000-insider-reality-check-487a4173a6f7cfabPharma Surgeen2026-07-21T23:58:13.000ZEnliven Therapeutics' Soaring Stock Faces a $570,000 Insider Reality Checkhttps://www.pharmaradar360.com/article/wall-street-can-wait-why-one-u-s-biotech-firm-is-listing-in-hong-kong-first-5e20bf3c1d22bd91Pharma Surgeen2026-07-21T23:48:28.000ZWall Street can wait: Why one U.S. biotech firm is listing in Hong Kong firsthttps://www.pharmaradar360.com/article/trump-says-generic-drugs-to-face-no-us-tariffs-for-2-years-then-100-and-200-tari-25650132ef47f0bbPharma Surgeen2026-07-21T23:40:07.000ZTrump says generic drugs to face no US tariffs for 2 years, then 100% and 200% tariffs laterhttps://www.pharmaradar360.com/article/fervor-over-top-selling-drugs-fuels-biotech-dealmaking-15ccc1f1460edc2fPharma Surgeen2026-07-21T23:16:00.000ZFervor over top-selling drugs fuels biotech dealmakinghttps://www.pharmaradar360.com/article/cambium-bio-raises-aud-1-008-million-via-placement-to-fund-phase-3-elate-ocular-f3cdd2b0611c8323Pharma Surgeen2026-07-21T23:15:03.000ZCambium Bio Raises AUD 1.008 Million via Placement to Fund Phase 3 Elate Ocular Trialhttps://www.pharmaradar360.com/article/senate-panel-examines-china-s-influence-on-u-s-drug-supply-chain-819968738d8cdf88Pharma Surgeen2026-07-21T22:26:06.000ZSenate Panel Examines China's Influence on U.S. Drug Supply Chainhttps://www.pharmaradar360.com/article/news-divcowest-lands-biotech-headquarters-deal-at-revamped-boston-tower-0528d33fd0f112edPharma Surgeen2026-07-21T22:19:58.000ZNews | DivcoWest lands biotech headquarters deal at revamped Boston towerhttps://www.pharmaradar360.com/article/on-the-run-for-20-years-most-wanted-fugitive-caught-hiding-as-a-biotech-exec-957547f6c6bc554fPharma Surgeen2026-07-21T22:04:56.000ZOn the run for 20 years, most-wanted fugitive caught hiding as a biotech exechttps://www.pharmaradar360.com/article/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosci-efd3d46d955447faPharma Surgeen2026-07-21T22:01:24.000ZPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002https://www.pharmaradar360.com/article/ai-toxicity-prediction-what-machine-learning-models-can-and-can-t-tell-you-about-b4d5c55cc313ba31Pharma Surgeen2026-07-21T21:36:56.000ZAI toxicity prediction: What machine learning models can (and can't) tell you about drug safetyhttps://www.pharmaradar360.com/article/fda-s-action-plan-for-ai-in-drug-development-what-scientists-need-to-know-9ad605b83a838b8ePharma Surgeen2026-07-21T21:36:55.000ZFDA's action plan for AI in drug development: What scientists need to knowhttps://www.pharmaradar360.com/article/threading-ai-throughout-the-drug-development-lifecycle-an-enterprise-lens-b535dcba076fcb12Pharma Surgeen2026-07-21T21:30:09.000ZThreading AI Throughout the Drug Development Lifecycle: An Enterprise Lenshttps://www.pharmaradar360.com/article/kansas-city-s-biotech-industry-gets-boost-with-38-1m-in-federal-funding-2881d96145d1a9b1Pharma Surgeen2026-07-21T21:24:03.000ZKansas City’s biotech industry gets boost with $38.1M in federal fundinghttps://www.pharmaradar360.com/article/most-wanted-fugitive-hid-out-for-21-years-as-a-biotech-exec-d8364014b7d3da7cPharma Surgeen2026-07-21T21:17:00.000ZMost-Wanted Fugitive Hid Out For 21 Years As A Biotech Exechttps://www.pharmaradar360.com/article/korea-s-kolon-tissuegene-shares-hit-9-month-low-after-knee-therapy-fails-us-phas-85cdea432cb135daPharma Surgeen2026-07-21T20:41:31.000ZKorea’s Kolon TissueGene shares hit 9-month low after knee therapy fails US phase 3 trialhttps://www.pharmaradar360.com/article/peptides-fda-may-ease-restrictions-despite-concerns-from-experts-a9293c0ca24eb6f3Pharma Surgeen2026-07-21T20:29:16.000ZPeptides: FDA May Ease Restrictions Despite Concerns From Expertshttps://www.pharmaradar360.com/article/fda-faces-staffing-crisis-threatening-u-s-drug-innovation-f2fae1c9e6c94753Pharma Surgeen2026-07-21T20:16:05.000ZFDA Faces Staffing Crisis Threatening U.S. Drug Innovationhttps://www.pharmaradar360.com/article/kolon-tissuegene-s-tg-c-fails-us-phase-3-trial-stock-hits-limit-down-k-bio-trust-6d6fb7cd4ddabf0dPharma Surgeen2026-07-21T20:05:00.000ZKolon TissueGene's TG-C Fails US Phase 3 Trial, Stock Hits Limit Down; K-Bio Trust Plummetshttps://www.pharmaradar360.com/article/gov-shapiro-announces-biotech-initiative-in-west-philadelphia-7748f8e99a1fb0daPharma Surgeen2026-07-21T19:38:03.000ZGov. Shapiro announces biotech initiative in West Philadelphiahttps://www.pharmaradar360.com/article/precautionary-medical-evacuation-following-a-potential-healthcare-related-exposu-b4f8fb936a6a6282Pharma Surgeen2026-07-21T19:35:00.000ZPrecautionary medical evacuation following a potential healthcare related exposure to Ebolahttps://www.pharmaradar360.com/article/frontier-bio-wins-phase-1-of-7m-nih-challenge-for-ai-powered-blood-brain-barrier-aff2beeaf1c95540Pharma Surgeen2026-07-21T19:15:52.000ZFrontier Bio Wins Phase 1 of $7M NIH Challenge for AI-Powered Blood-Brain Barrier Testinghttps://www.pharmaradar360.com/article/the-blueprint-for-a-bigger-medical-bureaucracy-part-3-news-article-9d0bf8c8b6c098ecPharma Surgeen2026-07-21T19:04:48.000ZThe Blueprint for a Bigger Medical Bureaucracy, Part 3: News Articlehttps://www.pharmaradar360.com/article/africa-s-most-developed-pharmaceutical-market-reviews-12-ozempic-generics-as-dru-8e64753d5eda5620Pharma Surgeen2026-07-21T18:28:58.000ZAfrica’s most developed pharmaceutical market reviews 12 Ozempic generics as drugmakers target Novo Nordisk’s dominancehttps://www.pharmaradar360.com/article/marijuana-rescheduling-fake-news-doesn-t-want-the-public-to-know-alj-hearing-gon-04eb225b0b93f562Pharma Surgeen2026-07-21T17:30:00.000ZMarijuana Rescheduling-Fake News Doesn't Want The Public To Know- ALJ Hearing Gone Wronghttps://www.pharmaradar360.com/article/danaher-s-revenue-outlook-cut-biotech-miss-overshadow-profit-forecast-raise-b6a83c4a35ec3b4bPharma Surgeen2026-07-21T17:20:39.000ZDanaher’s revenue outlook cut, biotech miss overshadow profit forecast raisehttps://www.pharmaradar360.com/article/the-u-s-china-biotech-race-has-begun-1fb4b2332b5f6a74Pharma Surgeen2026-07-21T17:19:47.000ZThe U.S.-China Biotech Race Has Begunhttps://www.pharmaradar360.com/article/why-some-scientists-are-worried-about-the-peptide-boom-0e9bdc391d9c16e5Pharma Surgeen2026-07-21T17:13:05.000ZWhy Some Scientists Are Worried About the Peptide Boomhttps://www.pharmaradar360.com/article/depo-provera-lawsuit-settlement-july-2026-litigation-update-1f899de08f3ef039Pharma Surgeen2026-07-21T17:09:58.000ZDepo Provera Lawsuit Settlement | July 2026 Litigation Updatehttps://www.pharmaradar360.com/article/daphne-koller-on-why-insitro-skipped-biotech-s-shortcut-0969986b5e90c069Pharma Surgeen2026-07-21T16:58:31.000ZDaphne Koller on Why Insitro Skipped Biotech’s Shortcuthttps://www.pharmaradar360.com/article/dimension-restocks-with-800m-to-capitalize-on-ai-s-rapid-ascent-46b084109ed7b6c6Pharma Surgeen2026-07-21T16:37:49.000ZDimension restocks with $800M to capitalize on AI’s ‘rapid ascent’https://www.pharmaradar360.com/article/is-lettuce-safe-to-eat-the-latest-on-the-cyclosporiasis-outbreak-56ea55f4716e8c5cPharma Surgeen2026-07-21T16:19:58.000ZIs Lettuce Safe to Eat? The Latest on the Cyclosporiasis Outbreakhttps://www.pharmaradar360.com/article/biotech-ipos-lead-2026-us-market-overshadowing-ai-firms-like-anthropic-da0817446f761482Pharma Surgeen2026-07-21T16:17:57.000ZBiotech IPOs lead 2026 US market, overshadowing AI firms like Anthropichttps://www.pharmaradar360.com/article/cordis-project-premature-newborn-motor-and-cognitive-impairments-early-diagnosis-652e409a7e61c11dPharma Surgeen2026-07-21T16:12:17.000ZCORDIS project: PremAtuRe nEwborn motor and cogNitive impairmenTs: Early diagnosishttps://www.pharmaradar360.com/article/novo-sues-lilly-alleging-misleading-advertising-of-obesity-drugs-15097471233056ffPharma Surgeen2026-07-21T16:12:07.000ZNovo sues Lilly, alleging ‘misleading’ advertising of obesity drugshttps://www.pharmaradar360.com/article/influenza-vaccines-marketed-in-the-uk-d048acae18525d12Pharma Surgeen2026-07-21T16:11:34.000ZInfluenza vaccines marketed in the UKhttps://www.pharmaradar360.com/article/inside-semmelweis-doceree-s-ai-bet-on-pharma-marketing-079248187b1f612dPharma Surgeen2026-07-21T16:10:54.000ZInside Semmelweis: Doceree's AI Bet on Pharma Marketinghttps://www.pharmaradar360.com/article/cordis-project-conect4children-collaborative-network-for-european-clinical-trial-a93f7e0c14db0f98Pharma Surgeen2026-07-21T16:10:06.000ZCORDIS project: conect4children (COllaborative Network for European Clinical Trials For Children)https://www.pharmaradar360.com/article/cordis-project-stem-cell-based-gene-therapy-for-recombination-deficient-scid-rec-fcd972b406fa4debPharma Surgeen2026-07-21T16:10:04.000ZCORDIS project: Stem-cell based gene therapy for recombination deficient SCID (RECOMB)https://www.pharmaradar360.com/article/cordis-project-diagnosis-and-management-of-febrile-illness-using-rna-personalise-fcbccf697b171c4fPharma Surgeen2026-07-21T16:10:02.000ZCORDIS project: Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosishttps://www.pharmaradar360.com/article/newly-upgraded-one-lincoln-tower-lands-its-first-biotech-tenant-fc0dabd84b23490cPharma Surgeen2026-07-21T16:07:27.000ZNewly upgraded One Lincoln tower lands its first biotech tenanthttps://www.pharmaradar360.com/article/national-mycobacterium-reference-service-south-user-handbook-ed8faef0a68eee13Pharma Surgeen2026-07-21T16:04:10.000ZNational mycobacterium reference service - South: user handbookhttps://www.pharmaradar360.com/article/mid-year-check-in-has-pharma-s-commercial-caution-lifted-609ce4c9a005c1afPharma Surgeen2026-07-21T15:55:54.000ZMid-Year Check-In: Has Pharma's Commercial Caution Lifted?https://www.pharmaradar360.com/article/why-japan-is-a-global-destination-for-regenerative-medicine-cb31225b9ea1fd84Pharma Surgeen2026-07-21T15:54:46.000ZWhy Japan is a global destination for regenerative medicinehttps://www.pharmaradar360.com/article/new-bill-senator-elizabeth-warren-introduces-s-4987-pharmaceutical-investment-ov-971025dd8de54856Pharma Surgeen2026-07-21T15:45:00.000ZNew Bill: Senator Elizabeth Warren introduces S. 4987: Pharmaceutical Investment Oversight and Accountability Acthttps://www.pharmaradar360.com/article/12a0e8e597109720Pharma Surgeen2026-07-21T15:30:00.000Z譲渡制限付株式報酬としての自己株式の処分に関するお知らせhttps://www.pharmaradar360.com/article/immunisation-3eb017cda8d80ce8Pharma Surgeen2026-07-21T15:29:34.000ZImmunisationhttps://www.pharmaradar360.com/article/masimo-keeps-634m-smartwatch-award-and-moves-to-appeal-b783ade7413f9fa4Pharma Surgeen2026-07-21T15:29:31.000ZMasimo keeps $634m smartwatch award and moves to appealhttps://www.pharmaradar360.com/article/novo-sues-lilly-after-alleged-misleading-and-false-advertising-campaign-8cbe7074ad3068b2Pharma Surgeen2026-07-21T15:25:25.000ZNovo sues Lilly after alleged misleading and false advertising campaignhttps://www.pharmaradar360.com/article/bacteriology-reference-department-user-manual-920f0fc90b06e74bPharma Surgeen2026-07-21T15:24:29.000ZBacteriology reference department user manualhttps://www.pharmaradar360.com/article/sepul-bio-completes-enrollment-in-phase-2b-luna-clinical-trial-of-ultevursen-for-96f94ef92da5d335Pharma Surgeen2026-07-21T14:37:15.000ZSepul Bio Completes Enrollment in Phase 2b LUNA Clinical Trial of Ultevursen for USH2A-Associated Retinitis Pigmentosahttps://www.pharmaradar360.com/article/biotech-ipo-gains-crush-ai-listings-with-standout-55-return-7e0811f9b52cb4f6Pharma Surgeen2026-07-21T14:26:11.000ZBiotech IPO Gains Crush AI Listings With Standout 55% Returnhttps://www.pharmaradar360.com/article/investigational-once-weekly-oral-hiv-treatment-regimen-of-islatravir-and-lenacap-8c13d824e3fa2349Pharma Surgeen2026-07-21T14:22:35.000ZInvestigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapyhttps://www.pharmaradar360.com/article/why-is-agio-stock-falling-today-d67c283664fb9f69Pharma Surgeen2026-07-21T14:09:02.000ZWhy Is AGIO Stock Falling Today?https://www.pharmaradar360.com/article/jupiter-enters-psychedelics-space-with-100m-deal-for-mdma-drug-b3ab855c44ee8e85Pharma Surgeen2026-07-21T14:00:40.000ZJupiter enters psychedelics space with $100M deal for MDMA drughttps://www.pharmaradar360.com/article/gilead-merck-s-phase-3-data-back-first-weekly-hiv-pill-52b8ef4281f78ae5Pharma Surgeen2026-07-21T14:00:00.000ZGilead, Merck’s phase 3 data back first weekly HIV pillhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-headquarters-lease-adds-to-one-lincoln-s-leasing-moment-43282e53efea013ePharma Surgeen2026-07-21T13:55:38.000ZCollegium Pharmaceutical Headquarters Lease Adds to One Lincoln's Leasing Momentum in Downtown Bostonhttps://www.pharmaradar360.com/article/this-new-biotech-might-have-solved-the-problem-with-long-term-space-missions-27bb20f98d5c7155Pharma Surgeen2026-07-21T13:47:00.000ZThis New Biotech Might Have Solved The Problem With Long-Term Space Missionshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-on-daikyo-deal-looks-closer-to-fully-valued-8b10f63a0ad5071aPharma Surgeen2026-07-21T13:45:29.000ZWest Pharmaceutical Services (WST) On Daikyo Deal Looks Closer To Fully Valuedhttps://www.pharmaradar360.com/article/beat-the-heat-hot-weather-advice-0f3647cb000e780cPharma Surgeen2026-07-21T13:37:06.000ZBeat the heat: hot weather advicehttps://www.pharmaradar360.com/article/anthropic-deepens-work-with-rare-disease-drugs-240c9c228f6da42ePharma Surgeen2026-07-21T13:36:28.000ZAnthropic deepens work with rare disease drugshttps://www.pharmaradar360.com/article/report-ri-fugitive-likely-worked-as-biotech-executive-e8ffe55a0d3ef161Pharma Surgeen2026-07-21T13:31:46.000ZReport: RI fugitive likely worked as biotech executivehttps://www.pharmaradar360.com/article/update-on-construction-of-new-plasma-derived-therapies-manufacturing-facility-in-d1631dff5b1be72fPharma Surgeen2026-07-21T13:28:13.000ZUpdate on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/20-000-takeda-employees-voted-to-select-four-new-global-corporate-social-respons-4ce0a7cb1b55185dPharma Surgeen2026-07-21T13:28:13.000Z20,000+ Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 countries | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-announces-completion-of-acquisition-of-own-shares-takeda-pharmaceuticals-1690c2b8dd2b1291Pharma Surgeen2026-07-21T13:28:13.000ZTakeda Announces Completion of Acquisition of Own Shares | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/filing-of-corporate-governance-report-to-the-tokyo-stock-exchange-takeda-pharmac-7d9747a68e4a6c88Pharma Surgeen2026-07-21T13:28:13.000ZFiling of Corporate Governance Report to the Tokyo Stock Exchange | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-announces-the-pricing-terms-of-the-previously-announced-cash-tender-offer-6b835e699995b023Pharma Surgeen2026-07-21T13:28:13.000ZTakeda Announces the Pricing Terms of the Previously Announced Cash Tender Offers for Certain Outstanding Notes | Takedahttps://www.pharmaradar360.com/article/takeda-announces-new-assignments-of-directors-10a83953d9c25a4dPharma Surgeen2026-07-21T13:28:13.000ZTakeda Announces New Assignments of Directorshttps://www.pharmaradar360.com/article/statement-on-inadvertent-abstract-disclosure-for-oveporexton-tak-861-by-world-sl-1f18034b19962b0aPharma Surgeen2026-07-21T13:28:08.000ZStatement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congresshttps://www.pharmaradar360.com/article/takeda-reports-third-quarter-fy2025-results-takeda-pharmaceuticals-14036fe34e09df4fPharma Surgeen2026-07-21T13:28:08.000ZTakeda Reports Third-Quarter FY2025 Results | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-completed-issuance-of-new-shares-and-disposal-of-treasury-shares-under-th-a48691ebb9c8bbe0Pharma Surgeen2026-07-21T13:28:08.000ZTakeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/takeda-phase-3-study-results-in-pediatric-ulcerative-colitis-a9ef7719579194c5Pharma Surgeen2026-07-21T13:28:08.000ZTakeda Phase 3 Study Results in Pediatric Ulcerative Colitishttps://www.pharmaradar360.com/article/u-s-fda-accepts-takeda-sbla-for-review-in-pediatric-uc-and-crohn-s-disease-e5af34c8063bc00fPharma Surgeen2026-07-21T13:28:08.000ZU.S. FDA Accepts Takeda sBLA for Review in Pediatric UC and Crohn’s Diseasehttps://www.pharmaradar360.com/article/rusfertides-phase-3-trial-for-polycythemia-vera-at-asco-2025-1a2bc3f4b3f44199Pharma Surgeen2026-07-21T13:28:08.000ZRusfertides Phase 3 Trial for Polycythemia Vera at ASCO 2025https://www.pharmaradar360.com/article/takeda-presents-long-term-data-from-advance-cidp-3-trial-of-hyqvia-733e0fb7ab2e8439Pharma Surgeen2026-07-21T13:28:08.000ZTakeda Presents Long-Term Data from ADVANCE-CIDP 3 Trial of HYQVIAhttps://www.pharmaradar360.com/article/takeda-to-hold-third-quarter-fy2022-earnings-call-on-february-2-2c1070c50282df17Pharma Surgeen2026-07-21T13:28:08.000ZTakeda to Hold Third Quarter FY2022 Earnings Call on February 2https://www.pharmaradar360.com/article/notice-concerning-withdrawal-of-shelf-registration-statement-and-filing-of-new-s-3f2e1b938aa6ce0aPharma Surgeen2026-07-21T13:28:02.000ZNotice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japanhttps://www.pharmaradar360.com/article/adzynma-receives-european-commission-approval-as-first-recombinant-adamts13-ther-f84e23ea1fc15610Pharma Surgeen2026-07-21T13:28:02.000ZADZYNMA® Receives European Commission Approval as First Recombinant ADAMTS13 Therapy for cTTPhttps://www.pharmaradar360.com/article/u-s-fda-approves-takeda-s-takhzyro-lanadelumab-flyo-to-prevent-hereditary-angioe-69d4a44f3b2773d8Pharma Surgeen2026-07-21T13:28:02.000ZU.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Olderhttps://www.pharmaradar360.com/article/takeda-to-acquire-exclusive-worldwide-ex-china-license-of-hutchmed-s-fruquintini-9ca0be57679fe064Pharma Surgeen2026-07-21T13:28:02.000ZTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitorhttps://www.pharmaradar360.com/article/dhsc-annual-statement-on-research-integrity-2025-to-2026-0e27c671da508172Pharma Surgeen2026-07-21T13:27:10.000ZDHSC annual statement on research integrity: 2025 to 2026https://www.pharmaradar360.com/article/fugitive-may-have-had-secret-career-in-biotech-b2a3f87bdcebb531Pharma Surgeen2026-07-21T13:25:00.000ZFugitive May Have Had Secret Career in Biotechhttps://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-novo-suing-lilly-over-deceptive-ads-a-fugitive-46f2f64ca44ccd01Pharma Surgeen2026-07-21T13:11:30.000ZPharmalittle: We're reading about Novo suing Lilly over 'deceptive' ads, a fugitive's secret life in biotech, and morehttps://www.pharmaradar360.com/article/nektar-therapeutics-announces-start-of-phase-3-zenith-ad-program-evaluating-nove-1517c5e2f04506ddPharma Surgeen2026-07-21T13:09:44.000ZNektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitishttps://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-to-present-and-plan-phase-3-ncp-trial-c60cab6b61aa9e08Pharma Surgeen2026-07-21T13:00:47.000ZOKYO Pharma (Nasdaq: OKYO) to present and plan Phase 3 NCP trialhttps://www.pharmaradar360.com/article/domperidone-new-contraindication-in-patients-with-phaeochromocytoma-due-to-the-r-5960dedb03d84cedPharma Surgeen2026-07-21T13:00:37.000ZDomperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertensionhttps://www.pharmaradar360.com/article/ukhsa-spend-over-500-2026-45a3f0a33e5a8499Pharma Surgeen2026-07-21T12:57:22.000ZUKHSA spend over £500: 2026https://www.pharmaradar360.com/article/boletin-del-comite-de-medicamentos-de-uso-humano-junio-de-2026-8431cf96ceb6628aPharma Surgeen2026-07-21T12:54:11.000ZBoletín del Comité de Medicamentos de Uso Humano. Junio de 2026https://www.pharmaradar360.com/article/boletin-del-comite-de-medicamentos-de-uso-humano-mayo-de-2026-9f27a607b2f0a8dePharma Surgeen2026-07-21T12:52:00.000ZBoletín del Comité de Medicamentos de Uso Humano. Mayo de 2026https://www.pharmaradar360.com/article/danaher-s-revenue-outlook-cut-biotech-miss-overshadow-profit-forecast-raise-ae91a6cc91961d18Pharma Surgeen2026-07-21T12:51:59.000ZDanaher’s revenue outlook cut, biotech miss overshadow profit forecast raisehttps://www.pharmaradar360.com/article/intelligent-bio-solutions-completes-precision-testing-strengthening-fda-510-k-su-455cadb9e00e10e7Pharma Surgeen2026-07-21T12:50:24.000ZIntelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Markethttps://www.pharmaradar360.com/article/intelligent-bio-solutions-completes-precision-testing-for-fda-510-k-submission-o-2ceac15089453745Pharma Surgeen2026-07-21T12:44:00.000ZIntelligent Bio Solutions Completes Precision Testing for FDA 510(k) Submission of Fingerprint Drug Screening System for Codeine Detectionhttps://www.pharmaradar360.com/article/which-is-the-better-healthcare-etf-first-trust-s-biotech-focused-fbt-or-state-st-8101a04f96861ddaPharma Surgeen2026-07-21T12:39:07.000ZWhich Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?https://www.pharmaradar360.com/article/israeli-polypid-signs-320-million-deal-to-sell-drug-preventing-surgical-infectio-1e3d88587ebf4d51Pharma Surgeen2026-07-21T12:35:49.000ZIsraeli PolyPid signs $320 million deal to sell drug preventing surgical infections in US, Canadahttps://www.pharmaradar360.com/article/biotech-ipo-gains-crush-ai-listings-with-standout-55-return-bc5d34b90f0c0941Pharma Surgeen2026-07-21T12:35:25.000ZBiotech IPO Gains Crush AI Listings With Standout 55% Returnhttps://www.pharmaradar360.com/article/which-is-the-better-healthcare-etf-first-trust-s-biotech-focused-fbt-or-state-st-f5c15ae2f615e09ePharma Surgeen2026-07-21T12:35:13.000ZWhich Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-stock-slides-20-with-a-9-day-losing-spree-80723ea97764a35dPharma Surgeen2026-07-21T12:33:45.000ZUltragenyx Pharmaceutical Stock Slides 20% With A 9-Day Losing Spreehttps://www.pharmaradar360.com/article/fingerprint-drug-screen-shows-repeatable-results-in-1-600-tests-d19876ed8f88366ePharma Surgeen2026-07-21T12:30:00.000ZFingerprint Drug Screen Shows Repeatable Results in 1,600 Testshttps://www.pharmaradar360.com/article/agios-says-adios-to-sickle-cell-program-over-lackluster-data-c24b4ba8e9adf17aPharma Surgeen2026-07-21T12:30:00.000ZAgios says adios to sickle cell program over lackluster datahttps://www.pharmaradar360.com/article/fda-approves-msd-s-lipfendra-as-first-oral-pcsk9-inhibitor-526f87b7cfbb80f1Pharma Surgeen2026-07-21T12:27:18.000ZFDA approves MSD’s Lipfendra as first oral PCSK9 inhibitorhttps://www.pharmaradar360.com/article/which-is-the-better-healthcare-etf-first-trust-s-biotech-focused-fbt-or-state-st-80ef801065e7ad02Pharma Surgeen2026-07-21T12:17:01.000ZWhich Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?https://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-abril-de-2026-0bf2a64f4466830dPharma Surgeen2026-07-21T12:16:32.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Abril de 2026https://www.pharmaradar360.com/article/pharmather-partners-with-ketamist-inventor-to-accelerate-fda-approval-of-needle-cda1c432d6822b79Pharma Surgeen2026-07-21T12:14:05.000ZPharmaTher Partners with KetaMist Inventor to Accelerate FDA Approval of Needle-Free Ketamine Therapyhttps://www.pharmaradar360.com/article/boletin-sobre-medicamentos-veterinarios-abril-junio-2026-02a9ba07952fe167Pharma Surgeen2026-07-21T12:14:04.000ZBoletín sobre Medicamentos Veterinarios. Abril- Junio 2026https://www.pharmaradar360.com/article/opinion-the-fda-s-505-b-2-pathway-is-an-underestimated-engine-of-value-creation-8f12728fe3a9886ePharma Surgeen2026-07-21T12:12:16.000ZOpinion: The FDA’s 505(b)(2) pathway is an underestimated engine of value creationhttps://www.pharmaradar360.com/article/anmat-dispone-la-baja-de-certificados-de-establecimientos-y-cancela-registros-de-e99cd36e17ce8d39Pharma Surgeen2026-07-21T12:08:57.000ZANMAT dispone la baja de certificados de establecimientos y cancela registros de productos médicos de distintas firmashttps://www.pharmaradar360.com/article/lilly-s-2-8-billion-bet-on-psychedelics-buys-science-that-conventional-trial-inf-68558c0d8002e981Pharma Surgeen2026-07-21T12:08:54.000ZLilly’s $2.8 Billion Bet on Psychedelics Buys Science That Conventional Trial Infrastructure May Not Be Able to Runhttps://www.pharmaradar360.com/article/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-in-adjunct-672e53d9f6ba05e1Pharma Surgeen2026-07-21T12:08:08.000ZHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedulehttps://www.pharmaradar360.com/article/sfda-grants-orphan-drug-designation-to-gritgen-therapeutics-for-pku-treatment-0f6ab801f6b87ab0Pharma Surgeen2026-07-21T12:00:00.000ZSFDA Grants Orphan Drug Designation to Gritgen Therapeutics for PKU Treatmenthttps://www.pharmaradar360.com/article/boston-children-s-broad-institute-and-the-jackson-laboratory-launch-the-center-f-9221e3cda1889097Pharma Surgeen2026-07-21T12:00:00.000ZBoston Children’s, Broad Institute, and The Jackson Laboratory launch the Center for Therapeutic Genetics, a non-profit effort to develop genetic medicines for rare and ultra-rare diseaseshttps://www.pharmaradar360.com/article/shimadzu-x-ray-high-voltage-generators-6fb0dddc89d347e3Pharma Surgeen2026-07-21T12:00:00.000ZShimadzu X-ray High Voltage Generatorshttps://www.pharmaradar360.com/article/mequ-a-s-om-warmer-leakage-0162fc45f38065fdPharma Surgeen2026-07-21T12:00:00.000ZMequ A/S ºM Warmer Leakagehttps://www.pharmaradar360.com/article/cardinal-health-presource-kits-containing-the-ritmed-neurological-sponges-3906497700436133Pharma Surgeen2026-07-21T12:00:00.000ZCardinal Health - Presource® Kits Containing the Ritmed® Neurological Spongeshttps://www.pharmaradar360.com/article/verrica-deal-could-bring-ycanth-to-israeli-children-if-approved-5e4874018ce09e11Pharma Surgeen2026-07-21T12:00:00.000ZVerrica deal could bring YCANTH to Israeli children if approvedhttps://www.pharmaradar360.com/article/axiom-biosciences-announces-intention-to-become-the-first-u-s-biotech-to-list-on-37b3f8159927e1f6Pharma Surgeen2026-07-21T11:56:44.000ZAxiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchangehttps://www.pharmaradar360.com/article/eledon-pharmaceuticals-stock-initiated-at-buy-by-rodman-renshaw-by-investing-com-ef33ab8dfab68846Pharma Surgeen2026-07-21T11:47:39.000ZEledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw By Investing.comhttps://www.pharmaradar360.com/article/cold-spring-biotech-showcases-blood-based-ptau217-test-for-early-alzheimer-s-det-5de516c7be508fd6Pharma Surgeen2026-07-21T11:44:00.000ZCold Spring Biotech Showcases Blood-Based pTau217 Test for Early Alzheimer's Detectionhttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-julio-de-2026-2da2f59b4c1cbb11Pharma Surgeen2026-07-21T11:37:30.000ZReunión del Comité de Medicamentos Veterinarios de julio de 2026https://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-junio-de-2026-780c990bfc3cefdePharma Surgeen2026-07-21T11:35:41.000ZReunión del Comité de Medicamentos Veterinarios de junio de 2026https://www.pharmaradar360.com/article/deprivation-of-liberty-safeguards-england-2025-to-2026-6a53d751c6544f4cPharma Surgeen2026-07-21T11:34:30.000ZDeprivation of Liberty Safeguards, England: 2025 to 2026https://www.pharmaradar360.com/article/jasper-and-kira-merge-to-build-immune-focused-biotech-403454fd208e19f3Pharma Surgeen2026-07-21T11:27:13.000ZJasper and Kira merge to build immune-focused biotechhttps://www.pharmaradar360.com/article/jupiter-neurosciences-nasdaq-juns-signs-definitive-agreement-for-exclusive-u-s-r-ae7a04182b35a4c6Pharma Surgeen2026-07-21T11:26:47.000ZJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Millionhttps://www.pharmaradar360.com/article/eledon-pharmaceuticals-stock-initiated-at-buy-by-rodman-renshaw-5e2d55a03fcd266cPharma Surgeen2026-07-21T11:20:00.000ZEledon Pharmaceuticals stock initiated at Buy by Rodman & Renshawhttps://www.pharmaradar360.com/article/summer-registration-exam-pass-rate-highest-since-2021-54bd4f0058a6166fPharma Surgeen2026-07-21T11:10:17.000ZSummer registration exam pass rate highest since 2021https://www.pharmaradar360.com/article/pharmala-biotech-executes-definitive-license-agreement-e32e15cb7cc9f78bPharma Surgeen2026-07-21T11:07:45.000ZPharmAla Biotech Executes Definitive License Agreementhttps://www.pharmaradar360.com/article/pharmala-biotech-executes-definitive-license-agreement-granting-jupiter-neurosci-570051b7b34eaa7cPharma Surgeen2026-07-21T11:06:15.000ZPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002https://www.pharmaradar360.com/article/axiom-biosciences-announces-intention-to-become-the-first-u-s-biotech-to-list-on-7cdf9a33b293e826Pharma Surgeen2026-07-21T11:02:00.000ZAxiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchangehttps://www.pharmaradar360.com/article/there-is-always-a-first-why-us-biotech-axiom-will-begin-its-ipo-journey-in-hong-ab53570559fc3044Pharma Surgeen2026-07-21T11:00:47.000Z‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Konghttps://www.pharmaradar360.com/article/okyo-pharma-chairman-gabriele-cerrone-boosts-stake-to-20-51-with-35-000-share-ac-58e26839372abe6fPharma Surgeen2026-07-21T11:00:11.000ZOKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trialhttps://www.pharmaradar360.com/article/healthcare-ipo-wave-us-biotech-firm-picks-hong-kong-over-nasdaq-for-listing-c803dedff3847054Pharma Surgeen2026-07-21T11:00:09.000ZHealthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listinghttps://www.pharmaradar360.com/article/a-new-era-for-surgery-with-real-time-ai-medtronic-to-unveil-touch-surgerytm-aide-79a9ea28f03da257Pharma Surgeen2026-07-21T11:00:00.000ZA new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026https://www.pharmaradar360.com/article/pbs-biotech-wins-2026-cell-products-development-of-the-year-award-5a7ac13649671983Pharma Surgeen2026-07-21T11:00:00.000ZPBS Biotech Wins 2026 Cell Products Development of the Year Awardhttps://www.pharmaradar360.com/article/pharmala-retains-ala-002-rights-outside-u-s-in-jupiter-license-b48900521d9a8852Pharma Surgeen2026-07-21T11:00:00.000ZPharmAla Retains ALA-002 Rights Outside U.S. in Jupiter Licensehttps://www.pharmaradar360.com/article/compugen-to-hold-1x1-meetings-at-july-28-29-btig-event-e6572d15f8e3f46ePharma Surgeen2026-07-21T11:00:00.000ZCompugen to Hold 1x1 Meetings at July 28-29 BTIG Eventhttps://www.pharmaradar360.com/article/altesa-biosciences-welcomes-seasoned-biotech-leader-brett-haumann-mbbch-mba-as-c-d885bab215f80fefPharma Surgeen2026-07-21T11:00:00.000ZAltesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officerhttps://www.pharmaradar360.com/article/novartis-q2-profits-recover-as-revenue-mantle-passes-to-newer-medicines-a1d1c54b74fc59a3Pharma Surgeen2026-07-21T10:54:56.000ZNovartis Q2 profits recover as revenue mantle passes to newer medicineshttps://www.pharmaradar360.com/article/shaanxi-kanghui-pharmaceutical-s-unit-signs-computing-power-service-contract-0daab72ddc007f7dPharma Surgeen2026-07-21T10:51:28.000ZShaanxi Kanghui Pharmaceutical's Unit Signs Computing Power Service Contracthttps://www.pharmaradar360.com/article/aaic26-alzheimer-s-disease-heterogeneity-calls-for-a-rethink-e927e48702e94fcfPharma Surgeen2026-07-21T10:49:55.000ZAAIC26: Alzheimer’s disease heterogeneity calls for a rethinkhttps://www.pharmaradar360.com/article/us-based-axiom-seeks-hong-kong-ipo-to-tap-china-s-biotech-boom-995709fac9821890Pharma Surgeen2026-07-21T10:45:00.000ZUS-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boomhttps://www.pharmaradar360.com/article/arbutus-takes-comirnaty-lnp-patent-fight-to-canada-and-upc-4589edd6afdb085dPharma Surgeen2026-07-21T10:37:55.000ZArbutus takes Comirnaty LNP patent fight to Canada and UPChttps://www.pharmaradar360.com/article/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-d7b92620baddc061Pharma Surgeen2026-07-21T10:28:42.000ZViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026https://www.pharmaradar360.com/article/bristol-myers-nvidia-join-forces-to-build-life-science-s-most-powerful-ai-factor-d5c10f2cf3a6b040Pharma Surgeen2026-07-21T10:14:54.000ZBristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factoryhttps://www.pharmaradar360.com/article/2026-changping-medical-healthcare-financial-investment-innovation-forum-integrat-4c46faeed629f615Pharma Surgeen2026-07-21T10:11:52.000Z2026 Changping Medical & Healthcare Financial Investment Innovation Forum: Integrating Industry Wisdom, Forging Trend-Driven Innovationhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-stock-extends-a-9-day-losing-streak-to-a-20-loss-6f618413c4ca3cd4Pharma Surgeen2026-07-21T10:07:01.000ZUltragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Losshttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-to-meet-investors-at-btig-biotech-event-832fa4a1deb1c32bPharma Surgeen2026-07-21T10:04:34.000ZAlterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech eventhttps://www.pharmaradar360.com/article/are-radiopharmaceutical-therapy-trials-designed-to-undertreat-46f62de00d634aa1Pharma Surgeen2026-07-21T10:00:00.000ZAre Radiopharmaceutical Therapy Trials Designed to Undertreat?https://www.pharmaradar360.com/article/securing-global-pharmaceutical-supply-chains-strategic-redundancy-local-manufact-7a35611e3bfce0adPharma Surgeen2026-07-21T09:39:31.000ZSecuring Global Pharmaceutical Supply Chains: Strategic Redundancy, Local Manufacturing, and Reimbursement Reform Take Center Stagehttps://www.pharmaradar360.com/article/swiss-national-bank-buys-941-700-shares-of-teva-pharmaceutical-industries-ltd-te-c0ab44710eb30639Pharma Surgeen2026-07-21T09:23:55.000ZSwiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/jennison-associates-llc-has-43-35-million-position-in-teva-pharmaceutical-indust-c374964c7a992780Pharma Surgeen2026-07-21T09:23:48.000ZJennison Associates LLC Has $43.35 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-21T09:08:28.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/fda-panel-to-revisit-biden-peptide-ban-as-it-weighs-looser-rules-185fed44a3162634Pharma Surgeen2026-07-21T09:05:00.000ZFDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Ruleshttps://www.pharmaradar360.com/article/is-recalled-lettuce-safe-after-false-positive-result-fda-issues-warning-5bbe5766cc6c77adPharma Surgeen2026-07-21T09:00:00.000ZIs recalled lettuce safe after false positive result? FDA issues warning